:: Main :: About :: Current Issue :: Archive :: Submit :: Contact ::
:: ::
Back to the articles list Back to browse issues page
BCG vaccine and pulmonary tuberculosis
SH Tafreshi *
R&D Department, Pasteur Institute of Iran, Alborz, Iran.
Abstract:   (340 Views)

Tuberculosis (TB) is one of the most important public health problems in the world and has been declared as a global emergency by the World Health Organization (WHO) in 1993. Bacillus Calmette-Guérin (BCG) is one of the first developed vaccines to prevent TB. Unfortunately, BCG vaccine has had a limited duration of protection and has shown controversial and variable levels of efficacy, especially against pulmonary TB. On the other hand, efforts in production of new forms of this vaccine have been in vain and revaccination is not considered as a suitable strategy to control the disease. Considering that TB affects adults mostly between the ages of 15 and 59, pulmonary TB is more common than disseminated TB and BCG vaccine has had a minimal effect on the global burden of pulmonary TB. Before introducing a new, safe and effective vaccine, combined strategies in the field of control and treatment of TB rather than vaccination are necessary.

Keywords: BCG, pulmonary TB, revaccination, efficacy, prevention.
Full-Text [PDF 365 kb]   (116 Downloads)    
Type of Study: Review article |
Received: 2017/06/20 | Accepted: 2017/06/20 | Published: 2017/06/20
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tafreshi S. BCG vaccine and pulmonary tuberculosis. vacres. 2016; 3 (8 and 9) :36-40
URL: http://vacres.pasteur.ac.ir/article-1-98-en.html
Back to the articles list Back to browse issues page
تحقیقات واکسن Vaccine Research
Persian site map - English site map - Created in 0.172 seconds with 826 queries by yektaweb 3470